Finally, considering the bone-derived biomarkers, ERA patients experiencing bone damage progression did not differ in terms of OPG, DKK1, and RANKL plasma levels compared with ERA patients not experiencing any bone damage progression (data not shown). The gene discussed is TNFRSF11B; the disease is enthesitis-related juvenile idiopathic arthritis.